体外心肺复苏后心脏骤停后综合征患者的细胞因子吸附(CYTER):单中心、开放标签、随机对照试验
CYTER为单中心、开放标签、随机对照试验,纳入弗赖堡大学医学中心接受体外心肺复苏的患者,1:1随机分入ECMO联合细胞因子吸附(CytoSorb吸附器整合入ECMO,每24小时更换,72小时后移除)或单纯ECMO。主要终点72小时血清IL-6浓度(意向性治疗分析)在两组间无显著差异(线性回归p=0.48)。30天生存率细胞因子吸附组14%(3/22)vs 对照组42%(8/19)(HR=1.85,95%CI 0.86-4.01;p=0.10),血管活性药支持及NSE、S100b、肌钙蛋白T、CRP、PCT水平组间相似。结论认为细胞因子吸附未降低IL-6,对生存、血管活性药支持或损伤标志物无显著影响。
要点
- 在ECPR后心脏骤停后综合征患者中,细胞因子吸附组与对照组72小时血清IL-6变化无显著差异(线性回归p=0.48)。
- 30天生存率细胞因子吸附组14%(3/22)vs 对照组42%(8/19),HR=1.85(95%CI 0.86-4.01),p=0.10,未达统计学显著。
- 血管活性药支持及NSE、S100b、肌钙蛋白T、CRP、PCT水平在两组间相似。
- CytoSorb吸附器整合入ECMO,每24小时更换,72小时后移除。
适用人群与场景
- 在弗赖堡大学医学中心(德国弗赖堡)接受体外心肺复苏(ECPR)的心脏骤停患者。
- 最终纳入50例患者,其中26例(52%)接受细胞因子吸附,24例(48%)未接受;9例因无法获得知情同意被排除,41例纳入主要分析。
处置流程与药物剂量
- 细胞因子吸附组:在ECMO回路中整合CytoSorb吸附器,每24小时更换,72小时后移除。
研究设计与关键结果
- 研究设计:单中心、开放标签、随机对照试验,1:1随机分配至ECMO联合细胞因子吸附或单纯ECMO。
- 主要终点:72小时血清IL-6浓度(意向性治疗分析)。细胞因子吸附组中位IL-6从408.0(93.4-906.5)降至324.0(134.3-4617.3)pg/mL,对照组从133.0(56.2-528.5)升至241.0(132.8-718.0)pg/mL;线性回归(细胞因子吸附 vs 对照)p=0.48。
- 次要终点:30天生存率细胞因子吸附组14%(3/22)vs 对照组42%(8/19),HR=1.85(95%CI 0.86-4.01),p=0.10。
- 血管活性药支持及NSE、S100b、肌钙蛋白T、CRP、PCT水平组间相似。
证据类型、等级与局限
- 证据类型:单中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:在ECPR患者中,细胞因子吸附未降低血清IL-6,对生存、血管活性药支持或损伤标志物无显著影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To investigate the effect of cytokine adsorption in patients receiving extracorporeal cardiopulmonary resuscitation (ECPR) after cardiac arrest.
METHODS: CYTER was a single-centre, open-label, randomised, controlled trial. Patients selected for ECPR at the University Medical Center Freiburg (Freiburg, Germany) were assigned to extracorporeal membrane oxygenation (ECMO) support with or without cytokine adsorption (1:1) using the CytoSorb adsorber, incorporated into the ECMO, replaced every 24 hours, and removed after 72 hours. The primary endpoint was serum interleukin (IL)-6 concentration at 72 hours (intention-to-treat analysis). Secondary endpoints included 30-day survival, vasopressor support and biomarkers of end-organ injury.
RESULTS: Of 50 patients enrolled in the trial, 26 (52%) were treated with cytokine adsorption and 24 (48%) without. Nine patients were excluded (informed consent could not be obtained); 41 patients were therefore included in the primary analysis. Median IL-6 levels (IQR) decreased from 408.0(93.4-906.5) to 324.0 (134.3-4617.3) pg/mL and increased from 133.0 (56.2-528.5) to 241.0 (132.8-718.0) pg/mL in the cytokine adsorption and control group, respectively (linear regression for treatment [cytokine adsorption vs control]: p = 0.48). Three (14%) of 22 patients treated with cytokine adsorption and 8 (42%) of 19 patients treated without cytokine adsorption survived to day 30 (HR = 1.85, 95% CI 0.86-4.01; p = 0.10). Vasopressor support and NSE, S100b, troponin T, CRP and PCT levels were similar between groups.
CONCLUSION: Cytokine adsorption in patients receiving ECPR did not reduce serum IL-6 and had no significant effect on survival, vasopressor support, or biomarkers of injury.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03685383.
参考来源
- Supady A, Zahn T, Kuhl M, et al. Cytokine adsorption in patients with post-cardiac arrest syndrome after extracorporeal cardiopulmonary resuscitation (CYTER) - A single-centre, open-label, randomised, controlled trial. Resuscitation. 2022. PMID: 35143902. doi:10.1016/j.resuscitation.2022.02.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。